| Effect of short-term losartan treatment in patients with primary aldosteronism and essential hypertension. | |
| | |
MedLine Citation:
|
PMID: 11523316 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The aim of this study was to investigate the effect of short-term treatment with losartan, a selective and competitive angiotensin II (AngII) receptor blocker, on vascular endothelial growth factor (VEGF), active renin and kallikrein activity (KA) in patients with essential hypertension and primary aldosteronism. Nine patients with primary aldosteronism (5 with Conn adenoma and 4 with idiopathic hyperaldosteronism) and 9 patients with essential hypertension were included in the study. Systolic and diastolic blood pressure decreased significantly after losartan treatment in both patient groups. Plasma and urinary Kallikrein activity were significantly higher in primary aldosteronism in comparison with essential hypertension. There were no significant changes in the active renin and aldosterone in patients with primary aldosteronism after treatment. Plasma and urinary KA decreased significantly after losartan administration in both groups. Serum VEGF levels in primary aldosteronism were not significantly different from those in essential hypertension and did not change significantly after treatment in either group. In conclusion, losartan, in usual therapeutic doses, lowers blood pressure in patients with primary aldosteronism and essential hypertension. This marked antihypertensive effect in primary aldosteronism could be explained predominantly by blockade of tissue renin-angiotensin system (RAS). The variations in KA could be due to hemodynamic changes. VEGF is not likely to be involved in the action of losartan. |
| | |
Authors:
|
S Zacharieva; I Atanassova; E Natchev; M Orbetzova; D Tzingilev |
Related Documents
:
|
12422136 - Clinical implications of aldosterone blockade. 7037816 - Low renin-aldosterone in "prehypertensive" young adults. 17659326 - A 'reverse' phylogenetic approach for identification of novel osmoregulatory and cardio... 19909806 - The role of 11β-hydroxysteroid dehydrogenase type 2 in human hypertension. 16825276 - Glaucoma progression is associated with decreased blood flow velocities in the short po... 1287376 - The effect of loop of henle diuretics on the tubuloglomerular feedback mechanism. |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Methods and findings in experimental and clinical pharmacology Volume: 23 ISSN: 0379-0355 ISO Abbreviation: Methods Find Exp Clin Pharmacol Publication Date: 2001 Apr |
Date Detail:
|
Created Date: 2001-08-28 Completed Date: 2002-03-14 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7909595 Medline TA: Methods Find Exp Clin Pharmacol Country: Spain |
Other Details:
|
Languages: eng Pagination: 153-6 Citation Subset: IM |
Affiliation:
|
Clinical Centre of Endocrinology and Gerontology, Medical University, National Oncological Centre, Sofia, Bulgaria. zacharieva@uheg.medicalnet-bg.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Age Factors Aldosterone / analysis Antihypertensive Agents / administration & dosage, pharmacology*, therapeutic use Blood Pressure / drug effects Endothelial Growth Factors / analysis Female Humans Hyperaldosteronism / drug therapy*, metabolism, physiopathology Hypertension / drug therapy*, metabolism, physiopathology Kallikreins / urine Losartan / administration & dosage, pharmacology*, therapeutic use Lymphokines / analysis Male Matched-Pair Analysis Middle Aged Plasma Kallikrein / analysis Receptor, Angiotensin, Type 1 Receptors, Angiotensin / antagonists & inhibitors* Renin / analysis Sex Factors Time Factors Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Endothelial Growth Factors; 0/Lymphokines; 0/Receptor, Angiotensin, Type 1; 0/Receptors, Angiotensin; 0/Vascular Endothelial Growth Factor A; 0/Vascular Endothelial Growth Factors; 114798-26-4/Losartan; 52-39-1/Aldosterone; EC 3.4.21.-/Kallikreins; EC 3.4.21.34/Plasma Kallikrein; EC 3.4.23.15/Renin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Long-term treatment with enalapril or losartan does not show antiproliferative effects in peripheral...
Next Document: The way in which intervention studies have "personality" and why it is important to meta-analysis.